| Ezetimibe and vascular endothelial function. | |
| | |
MedLine Citation:
|
PMID: 21044017 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de novo cholesterol synthesis in the liver. Statins also have beneficial pleiotropic effects on the atherosclerotic process that are independent of their ability to lower lipid values. However, the levels of low-density lipoprotein cholesterol (LDL-C) in most hypercholesterolemic patients at high risk for cardiovascular disease do not reach the goals proposed by guidelines even when prescribed with statins. Ezetimibe is a new lipid-lowering agent that blocks the intestinal absorption of dietary and biliary cholesterol and reduces LDL-C levels, especially when combined with statins. However, its effect on cardiovascular events remains unknown. We reviewed the effects of ezetimibe on cardiovascular diseases, in particular, vascular endothelial function, which is initially impaired during the atherogenetic process and is an important predictor of cardiovascular events. The simultaneous inhibition of cholesterol synthesis by statin and of cholesterol absorption by ezetimibe might retard the atherogenetic process. These effects are considered to be mainly mediated by lipid lowering. However, further studies should elucidate the mechanism of the anti-atherosclerotic effects induced by ezetimibe; for instance, whether or not it directly affects atherogenesis independently from its lipid-lowering effects. |
| | |
Authors:
|
Satoshi Ikeda; Koji Maemura |
Related Documents
:
|
18292607 - Cholesterol in end-stage renal disease: the good, the bad or the ugly? 10190397 - Simvastatin decreases aldehyde production derived from lipoprotein oxidation. 16866917 - Cholesterol, statins and tau. 9571327 - Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemf... 8294167 - Evaluation of the effect of different kinds of foods on the bioavailability of a sustai... 14504177 - Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current vascular pharmacology Volume: 9 ISSN: 1875-6212 ISO Abbreviation: Curr Vasc Pharmacol Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-11-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101157208 Medline TA: Curr Vasc Pharmacol Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 87-98 Citation Subset: IM |
Affiliation:
|
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in...
Next Document: New concept of vascular calcification and metabolism.